Syracuse, NYNCT05656469Now EnrollingIRB Ready

Mood Disorders Clinical Trial in Syracuse, NY

Access cutting-edge mood disorders treatment through this clinical trial at a research site in Syracuse. Study-provided care at no cost to qualified participants.

Sponsored by Parnassia Groep

Quick Self-Assessment

See if you qualify for this Syracuse location

Preparing your pre-screening questions…

Expert Care in Syracuse

Access mood disorders specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related mood disorders treatment provided free

Apply for This Syracuse Location

Check if you qualify for this mood disorders clinical trial in Syracuse, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Syracuse

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Syracuse site if eligible
  4. 4Begin participation

About This Mood Disorders Study in Syracuse

A 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric patients suffering from mood, anxiety, or psychotic disorders.

Sponsor: Parnassia Groep

Who Can Participate

Inclusion Criteria

Suffer from a depressive episode (major depressive disorder and bipolar disorder (currently depressive episode)) (as assessed by the MINI International Neuropsychiatric Interview (M.I.N.I.) in agreement with Diagnostic and Statistical Manual (DSM-5 criteria) of at least moderate severity (assessed using the Structured Interview Guide for the Hamilton Depression Scale (SIGH-D) with a score of 14 or higher) and/or suffer from an anxiety disorder (panic disorder, generalised anxiety disorder) (as assessed by the M.I.N.I. in agreement with DSM-5 criteria) of at least moderate severity (assessed using the Structured Interview Guide for the Hamilton Anxiety Scale (SIGH- A) with a score of 18 or higher) and/or suffer from a psychotic disorder (schizophrenia and schizoaffective disorder) (as assessed by the M.I.N.I. in agreement with DSM-5 criteria) of at least moderate severity (assessed using the Positive and Negative Symptom Scale (PANSS) with a score of 75 or higher).
Have had an inadequate response to at least 1 psychotropic treatment during their life-time. Inadequate response is defined as insufficient efficacy of a psychotropic treatment when dosed high enough and maintained long enough, or discontinuation of a psychotropic treatment due to AEs or intolerability.
Are about to switch (or have switched within the last 2 weeks prior to first contact with an investigator) to sertraline or escitalopram (for patients with mood or anxiety disorders), or to aripiprazole or risperidone (for patients with psychotic disorders) due to an inadequate response to or intolerance of the current/ previous medication.
Currently receiving inpatient or outpatient psychiatric treatment.
Be able to understand the requirements of the study and provide written informed consent to participate in this study; a signed and dated informed consent form (ICF) will be obtained from each patient before participation in the study.
To give written consent to the use and disclosure of clinical data from their medical records for the purpose of this study.
Age between ≥16 and \<70 years.
Ownership of a mobile phone (Android or iOS operation system) for passive monitoring.

Exclusion Criteria

Patients with a history of prior pharmacogenomic testing
Patients with no prior use of psychotropic medication (medication-naïve patients)
Severe somatic comorbidities as reported in the subject's medical history or based on clinical chemistry/electrocardiography (ECG) results up to six months ago. If any of these comorbidities is detected on the basis of physical examination and/or clinical chemistry and/or ECG at the screening visit, participation is not possible.
Liver disease defined as follows: Alanine-Aminotransferase (ALAT) \>70u/L
Renal disease: Estimated glomerular filtration rate (eGFR) \< 60ml/min/1.73m2
Diabetes: Blood glucose \> 11.1 mmol/L or twice a fasting glucose \> 7.0 mmol/L
Cardiac disease: prolonged QT-interval.
Alcohol and/or substance abuse and/or dependence (except nicotine)
Polypharmacy defined as the routine use of five or more medications including over- the-counter, prescription and/or traditional and complementary medicines used by a patient (WHO 2019).
Inability to use the mobile phone application
Pregnant or breastfeeding women

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Syracuse?

Yes, this clinical trial (NCT05656469) has an active research site in Syracuse, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Mood Disorders Treatment Options in Syracuse, NY

If you're searching for mood disorders treatment options in Syracuse, NY, this clinical trial (NCT05656469) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Syracuse research site is actively enrolling participants for this clinical trial. You'll receive care from experienced mood disorders specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all mood disorders clinical trials near you to find additional studies recruiting in your area.

More Bipolar Disorder Trials in Syracuse, NY

See all bipolar disorder clinical trials recruiting in Syracuse — not just this study.

Browse Bipolar Disorder Trials in Syracuse →

Browse More Trials by Condition

Bipolar Disorder TrialsAll Conditions →

Ready to Join in Syracuse?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Syracuse, NY